Navigation Links
Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today that results of preclinical studies with its lead product candidate, XMT-1001, will be presented in two posters at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) taking place April 14-18th in Los Angeles, CA. Full text of the abstracts can be viewed online at the AACR website at http://www.AACR.org.

The presentation schedule is as follows:

Abstract #781 "XMT-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model" will be presented in a poster session on Sunday, April 15th from 8:00 am - 12:00 pm. Alex Yurkovetskiy and Russell C. Petter are the presenting authors.

Abstract #4723 "Pharmacokinetics of a novel camptothecin conjugate (XMT- 1001) in the rat and dog" will be presented in a poster session on Tuesday, April 17th from 1:00 - 5:00 pm. Ullrich Schwertschlag and Alex Yurkovetskiy are the presenting authors.

About XMT-1101

XMT-1001 is Mersana's most advanced Fleximer(R)-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer, showing extended plasma half-life and high concentrations in tumor tissue.

About Fleximer Technology

Fleximer(R) technology improves the therapeutic index of cytotoxic compounds useful as anti-cancer agents by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized
'"/>




Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/23/2014)... Sept. 23, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ... Shrotriya , MD, Chairman and Chief Executive Officer of ... appointment was made in connection with the recently announced ...
(Date:9/23/2014)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... address unmet medical needs in the areas of ... has appointed Rasappa Arumugham , PhD, as ... has over 25 years of diverse experience in ... of formulation research, analytical method development, quality control ...
(Date:9/23/2014)... Sept. 23, 2014  As physicians seek information ... communication channels to learn about new therapies or ... from a new report by global sales and ... that communicating via a customized mix of digital ... best opportunity to engage with physicians. And, productive ...
Breaking Medicine Technology:CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 2Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 3Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5
(Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock ... Auditorium Seattle concert posters. The Doors were a smash hit ... year. The Seattle Eagles Auditorium concert was held on July ... to Eagles Auditorium in November the same year. The artist ... comes in three colors. The poster is a split fountain ...
(Date:9/23/2014)... News) -- Few children who take medication for ... the rates vary six-fold across counties in the ... alone can manage symptoms for many children with ... receive behavioral therapy (psychotherapy), the Rand Corp. researchers ... than 1,500 counties across the United States that ...
(Date:9/23/2014)... national report showing the benefits of preventing a ... Medicaid services was released today by the American ... Congress Must Save the Medicaid Primary Care Pay ... Access to Life-Saving Primary Care Will Expire," explains ... access to internists and pediatricians (and their related ...
(Date:9/23/2014)... Texas (PRWEB) September 23, 2014 ... for allergic rhinitis (AR) is highly fragmented, ... different SIT formulations available, under different regulatory ... between markets. Europe has the most developed ... (SLIT), and allergen immunotherapy tablets (AITs) all ...
(Date:9/23/2014)... York, New York (PRWEB) September 23, 2014 ... forward in courts around the country, Bernstein Liebhard LLP ... Court, Middle District of Florida on September 19th, the ... from a case filed in that jurisdiction on behalf ... growth) and other complications due to his use of ...
Breaking Medicine News(10 mins):Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3
... The makers of the WaveSense(TM) line of blood ... commitment to providing low cost, high accuracy, and high ... diabetes. The WaveSense Presto(TM) BGM can be found at ... strips (50 ct) are often as low as $22.88, ...
... The Hazelden Foundation, one of the world,s largest and ... centers, announced today that the Rev. Michael J. O,Connell ... of Trustees. O,Connell succeeds Norbert J. Conzemius, who served ... http://www.newscom.com/cgi-bin/prnh/20061128/CGTU038LOGO ) , , "The Rev. O,Connell ...
... -- GHX honored 12 healthcare provider and supplier ... chain performance. The awards were presented on Wednesday, June 3, ... Annual GHX Supply Chain Summit - the largest forum in ... of the healthcare supply chain. , , The theme ...
... in Under 4 years , , PLEASANTON, Calif., June ... Photopneumatic system in the United States. The installation of the ... base to approximately 1800 systems worldwide. The company has direct ... of distributors in over 20 countries in Asia, Europe and ...
... , , ... ANDS ) announced that it has entered into ... in gross proceeds in a "registered direct" offering through the ... estimates that net proceeds from the offering will be approximately ...
... 4 As the administration moves forward with health care ... research released this week by the Deloitte Center for Health ... Diego highlights how comparative effectiveness and consumerism will challenge the ... , During a time when the majority of U.S. consumers ...
Cached Medicine News:Health News:WaveSense Reduces Diabetes Testing Cost by 50% 2Health News:The Rev. Michael J. O'Connell Assumes Chairmanship of Hazelden Foundation Board of Trustees 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 3Health News:Aesthera Announces Installation of 1000th Photopneumatic System in US 2Health News:Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering 2Health News:Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering 3Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 2Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 3Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 4Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 5
... HIV-1 Antibody Test (Reveal Test) is MedMiras ... antibodies in human serum or plasma against ... in response to HIV infection. The Reveal ... membrane technology, and is comprised of a ...
... The OraQuick ADVANCE Rapid ... a single-use, qualitative immunoassay ... Human Immunodeficiency Virus Type ... 2 (HIV-2) in oral ...
... The advanced performance benefits ... been applied to the ... Implants) Upper Extremity Plates. ... combine to provide a ...
... of TiMAX material have been applied to a ... and an ultra-low profile combine to provide a ... extremity. , ,This complete set of periarticular plates ... , Fibula Composite Plate , Spider ...
Medicine Products: